Nonalcoholic fatty liver disease, more recently known as metabolic dysfunction-associated steatotic liver disease (MASLD), affects nearly 1 in 4 adults. Left untreated, patients with MASLD can suffer metabolic, cardiovascular, and liver-related complications including cirrhosis and death. Noninvasive tests are widely available to screen patients at risk of MASLD. Weight loss and cardiovascular risk reduction, followed by directed pharmacotherapy, are the mainstays of treatment.In this 1-hour journal-style review article, supplemented with video clips of key concepts, Drs. Jay Shubrook and Arun Sanyal provide their insights about the primary care identification, diagnosis, and treatment of patients with MASLD.
Course Credit:
1 AMA PRA Category 1 CreditTM
1 ANCC Contact Hour
1 CA-BRN Contact Hour
0.5 Pharmacology Hours
Dates:
Opens: 2024-01-26
Closes: 2025-02-01
Target Audience:
The primary target audience includes healthcare professionals who care for patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), with a focus on primary care providers (MD, PA, and NP).
This program is supported by an educational grant provided by Novo Nordisk.
Accreditation
The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1 contact hour, including 0.5 pharmacology hours.
To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.
Additional Content Planners
Heather Jimenez, MSN, FNP-C (Nurse Reviewer)No significant relationships to disclose.
Kam A. Newman, MD (Peer Reviewer)
No significant relationships to disclose.
Michael Smith, PharmD, BCPS (Medical Writer)
Consultant: Wolters-Kluwer
Annenberg Center for Health Sciences
Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant financial relationships to disclose.
All of the financial relationships listed for these individuals have been mitigated.
-
Arun J. Sanyal, MD
Director, Stravitz-Sanyal Institute for Liver Disease and Metabolic Health
Interim Chair, Division of Gastroenterology, Hepatology, and Nutrition
Virginia Commonwealth University Medical Center
Richmond, Virginia -
Jay H. Shubrook, DO
Director of Clinical Research and Diabetes Services
TUCA/Solano County Family Health Services
Professor, and Interim Chair
Department of Clinical Sciences and Community Health
Touro University California College of Osteopathic Medicine
Vallejo, California
Presenting Faculty
Downloads
Learning Objectives
- Recognize patients at high risk for developing NASH.
- Determine the utility of noninvasive tests and biomarkers for routine clinical practice to diagnose, stage, and monitor patients with NASH.
- Apply the guideline-recommended therapies that target associated comorbidities earlier in the course of disease for patients with NASH as recommended by AASLD.
- Formulate multidisciplinary strategies to improve the early diagnosis and treatment of patients with NASH.
Faculty Disclosures
Arun J. Sanyal, MD
Consultant: Akero, Alnylam, AstraZeneca, Biocellvia, Boehringer Ingelheim, Eli Lilly, FibroNest, Fractyl, Genentech, Gilead, GlaxoSmithKline, HistoIndex, Intercept, Inventiva, Madrigal, Merck, NorthSea, Novo Nordisk, Novartis, Path-AI, Pfizer, Regeneron, Roche, Takeda, TARGET PharmaSolutions, Terns
Stock Options: Durect, Genfit, HemoShear, Inversago, Tiziana
Jay H. Shubrook, DO
Advisory Board: AstraZeneca, Bayer, Eli Lilly, Nevro, Novo Nordisk
Consultant: Abbott